Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight

Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight (CRESSOB)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00584519

Acronym

CRESSOB

Enrollment

430

Registered

2008-01-02

Start date

2007-06-30

Completion date

2009-06-30

Last updated

2021-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

Schizophrenia, Overweight, Cardiovascular Risk, Obesity

Brief summary

To analyse the progress of modifiable metabolic risk factors (Blood pressure, cigarette smoking, waist perimeter, BMI, glycemia and lipidic profile) in schizophrenic patients with overweight for 12 months. To analyse the perceived health status and the level of functioning and disability of patients with schizophrenia and overweight and their progress at 3, 6 and 12 months. To assess the progress of the symptoms of the disease at 6 and 12 months.

Detailed description

Consecutive patient sampling. Any investigational site four consecutive patients with diagnosis of Schizophrenia (DSM-IV TR) and Overweight (BMI more or equal to 25 Kg/m2)

Interventions

OTHERnon-interventional

non-interventional

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (DSM-IV TR) * Patients with BMI (body mass index) more or equal to 25 Kg/m2 * Patients or their legal representative have provided written informed consent

Exclusion criteria

* Patients are unable to complete or to understand health questionnaires in Spanish language * Patients are currently enrolled on clinical trials or other investigational studies

Design outcomes

Primary

Measure	Time frame
Evolution of modifiable metabolic risk factors (Blood pressure, cigarette smoking, waist perimeter, BMI, glycemia and lipidic profile) in schizophrenic patients with overweight for 12 months.	12 months

Secondary

Measure	Time frame
Current Pattern of Treatment in this Population	12 months
Cardiovascular Risk	12 months
To assess the progress of the symptoms and clinical evolution of the disease	12 months
Patient Functional Impairment	12 months
Patient Quality of Life	12 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026